In the year since its devastating hack, 23andMe has lost all of its value and most of its governing board — and somehow, ...

Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...

The genetic testing firm will also close its drug development arm. CEO Anne Wojcicki said the cuts are necessary to “focus on ...

The DNA testing kit company is also discontinuing new developments to its therapeutics program, which has been focused on ...

In a significant move to stabilize its operations, 23andMe has announced the layoff of 200 employees, representing a ...

“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core ...

Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to ...

investigators and study staff for their participation in our clinical trials,” co-founder and CEO Anne Wojcicki said in a ...

In a prepared statement, 23andMe CEO and co-founder Anne Wojcicki said the company was "taking these difficult but necessary ...

The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies ...

As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.

Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at ...